Ignite Creation Date:
2024-05-06 @ 1:22 PM
Last Modification Date:
2024-10-26 @ 1:13 PM
Study NCT ID:
NCT04005144
Status:
TERMINATED
Last Update Posted:
2022-10-17
First Post:
2019-06-28
Brief Title:
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Conditions & Keywords Data
Conditions:
| Name |
|---|
| ALK Gene Rearrangement |
| Lung Non-Small Cell Carcinoma |
| Progressive Disease |
| ROS1 Gene Rearrangement |
| Stage IIIB Lung Cancer |
| Stage IIIC Lung Cancer |
| Stage IV Lung Cancer |
| Stage IVA Lung Cancer |
| Stage IVB Lung Cancer |
Keywords: